ZyVersa Therapeutics explores cost cuts, potential going dark, and asset sales; director Park resigns

ZyVersa Therapeutics, Inc.

Director Min Chul Park resigned effective July 8, 2026, for personal reasons, no disagreement with company.
CEO Stephen Glover and CFO Peter Wolfe voluntarily accepted reduced compensation to preserve cash.
Company considering divesting VAR 200 or IC 100 product candidates and reducing headcount.
Company may go dark by suspending SEC reporting obligations under Rule 12h-3.
Also evaluating sale of company or assets, restructuring, or reorganization to maximize shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.